基因组编辑
核糖核蛋白
清脆的
体内
质粒
Cas9
核糖核酸
核酸
限制
基因组
引导RNA
计算生物学
生物
工程类
遗传学
基因
机械工程
作者
Cong‐Fei Xu,Guojun Chen,Ying‐Li Luo,Yue Zhang,Gui Zhao,Zi-Dong Lu,Anna Czarna,Zhen Gu,Jun Wang
标识
DOI:10.1016/j.addr.2019.11.005
摘要
The CRISPR-Cas system initiated a revolution in genome editing when it was, for the first time, demonstrated success in the mammalian cells. Today, scientists are able to readily edit genomes, regulate gene transcription, engineer posttranscriptional events, and image nucleic acids using CRISPR-Cas-based tools. However, to efficiently transport CRISPR-Cas into target tissues/cells remains challenging due to many extra- and intra-cellular barriers, therefore largely limiting the applications of CRISPR-based therapeutics in vivo. In this review, we summarize the features of plasmid-, RNA- and ribonucleoprotein (RNP)-based CRISPR-Cas therapeutics. Then, we survey the current in vivo delivery systems. We specify the requirements for efficient in vivo delivery in clinical settings, and highlight both efficiency and safety for different CRISPR-Cas tools.
科研通智能强力驱动
Strongly Powered by AbleSci AI